CEO and President, Altegra Health
Miami Lakes, FL
With more than 25 years of start-up, deal-making and operating experience in healthcare services and life sciences, Kevin joined Altegra Health, formerly Social Services Coordinators, in April 2009 to oversee the organizations day-to-day operations. Altegra Health is the leading provider of eligibility-based revenue-cycle management services to health plans nationwide. As President and Chief Executive Officer, Kevin’s responsibilities include Outreach and Operations, Information Technology, Product Development, Sales and Account Management, Government Relations, Finance and Project Management.
Prior to joining Altegra Health, Kevin was an executive-in-residence with Bain Capital Ventures and SV Life Sciences. He previously served as Executive Vice President and Chief Development Officer of PolyMedica Corporation, Senior Vice President of BG Medicine, and Chief Operating Officer of the Synergy Informatics division of Quintiles Transnational.
Kevin holds a BA in Psychology from Columbia University and an MBA from Harvard Business School.
Chairman and CEO, PolyRemedy, Inc.
A life sciences executive with a successful track record driving growth by building patient-focused companies, Mark joined PolyRemedy in January 2010. He was previously President and CEO of HyperMed, Inc., a commercial stage start-up medical device company dedicated to improving the diagnosis and associated outcomes of advanced vascular interventions using novel hyperspectrial imaging technology. Most relevant to PolyRemedy, Mark was President USA of Kinetic Concepts Inc. (NYSE: KCI), a leading global medical technology company in advanced wound care whose breakthrough technology has enabled clinicians to improve the lives of over 1 million patients. At KCI, he reinvigorated the business by growing revenues from $650 million to $950 million and expanding company profits by 62 percent over 20 months.
As VP Corporate Development for OraPharma, Inc., a drug-device combination therapy to treat periodontal disease, he co-led a successful IPO and eventual sale to Johnson & Johnson. Mark also served in various sales, marketing and manufacturing roles with Eli Lilly and Company and was a member of The Boston Consulting Group for six years.
Mark holds an MBA from the Wharton School at the University of Pennsylvania and a BS in Industrial Engineering from Penn State University.
Managing Partner, Flybridge Capital Partners
Michael is a General Partner at Flybridge Capital Partners, focused on information technology, healthcare and medical technology investments with a particular focus on opportunities involving the convergence of healthcare and IT and technology-enabled business services.
Prior to Flybridge, Michael served in senior positions at Polaris Venture Partners, GCC Investments, Wasserstein Perella & Co., Morgan Stanley & Co. and Credit Suisse First Boston.
Michael currently serves on the board of the National Venture Capital Association, as Chair of the Entrepreneurship Committee of the Massachusetts Information Collaborative, and as co-Founder of the 12 x 12 program. He also serves on the investment committee of the Parners Innovation Healthcare Fund, is a member of the Executive Business Advisory Council for Mass General Hospital for Children, and a trustee and investment committee member for the Massachusetts Eye and Ear Infirmary.
Michael received a BA with honors in Chemistry from Williams College and an MBA from Harvard Business School.
Partner, MedVenture Associates
Charles Liamos joined MedVenture Associates in September 2006 as Executive in Residence and became a Partner in January 2007. He brings more than 10 years of experience in finance and operations leadership positions and more than 11 years in the diabetes market, where he had leadership roles in developing technologies and growing businesses.
Prior to joining MVA, Charlie was President and CEO of Fovioptics, Inc., a medical device company focused on blood glucose monitoring. He previously served as Chief Operating Officer and Chief Financial Officer of TheraSense, Inc.
Charlie holds a BS in Finance from University of Vermont, Burlington, and is a graduate of GEs Financial Management Program. In addition to serving on the PolyRemedy board, he currently sits on the boards of Insulet Corp., OptiScan Biomedical, Sonoma Orthopedic Products, Inc., SoundID, Inc., Southern Implants, Inc., and Vital Therapies, Inc.
General Partner, Delphi Ventures
Menlo Park, CA
Doug is a General Partner at Delphi Ventures, focused on medical devices and diagnostics. Prior to Delphi, Doug served as an Associate with Alex. Brown’s Healthcare Investment Banking Group in San Francisco. While at Alex. Brown, Doug assisted in the execution of over dozen financing and merger transactions involving both Fortune 500 and venture backed medical technology companies.
In addition to serving on the PolyRemedy board, Doug currently sits on the board of the following companies: Anulex Technologies Inc., Ivantis, Inc., Tandem Diabetes, Care, Inc., TriVascular, Inc., and Vibrynt, Inc.
Doug holds an AB from Dartmouth College located in Hanover, New Hampshire.
Partner, Advanced Technology Ventures
Palo Alto, CA
Stephen is a technology partner at ATV (early stage) and Galen (later stage), focusing on medical devices. Steve has been a managing director at The Wilkerson Group, where he was in charge of the medical device practice. Other previous employment includes director of technology and new business development at Becton Dickinson & Co., and various technical management and strategic planning positions with Union Carbide Clinical Diagnostics. He is a director of Aperio, USHIFU, Cambrooke Foods and Pacific Diagnostic Labs. Stephen holds an M.S. in Biomedical Engineering Studies and Medical Physics from the University of California, Berkeley and a B.S. from MIT.